Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis

Therapeutic Advances in Neurological Disorders
F SellebjergDaniel Mikol

Abstract

Multiple sclerosis (MS) is a common and chronic central nervous system (CNS) demyelinating disease and a leading cause of permanent disability. Patients most often present with a relapsing-remitting disease course, typically progressing over time to a phase of relentless advancement in secondary progressive MS (SPMS), for which approved disease-modifying therapies are limited. In this review, we summarize the pathophysiological mechanisms involved in the development of SPMS and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of MS, to exert beneficial effects in reducing disease progression unrelated to relapses in SPMS. In both forms of MS, active brain-tissue injury is associated with inflammation; but in SPMS, the inflammatory response occurs at least partly behind the blood-brain barrier and is followed by a cascade of events, including persistent microglial activation that may lead to chronic demyelination and neurodegeneration associated with irreversible disability. In patients with relapsing forms of MS, natalizumab therapy is known to significantly reduce intrathecal inflammatory responses which results in reductions in brain lesions and brain atrop...Continue Reading

References

Jan 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·D KiddA J Thompson
Nov 17, 1998·Seminars in Neurology·B G Weinshenker
Jul 30, 1999·Journal of Neuroimmunology·W F Hickey
Feb 29, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M ColomboM Ferrarini
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Jan 3, 2003·The New England Journal of Medicine·David H MillerUNKNOWN International Natalizumab Multiple Sclerosis Trial Group
Aug 21, 2003·Multiple Sclerosis : Clinical and Laboratory Research·L BøS J Mørk
Apr 27, 2005·Neurology·George P A RicePeter A Calabresi
Jul 27, 2005·Journal of Neurology·Alasdair J ColesD Alastair Compston
Oct 19, 2005·Brain : a Journal of Neurology·Alexandra KutzelniggHans Lassmann
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Sep 29, 2006·Neurobiology of Disease·Jack van HorssenHelga E de Vries
Mar 21, 2007·Journal of the Neurological Sciences·Hans Lassmann
Apr 25, 2007·Neurology·D H MillerUNKNOWN AFFIRM Investigators
May 10, 2007·Current Neurology and Neuroscience Reports·Hans Lassmann
Sep 21, 2007·Annals of Neurology·Nathalie KoningInge Huitinga
Oct 5, 2007·Neurology·N M MollRichard M Ransohoff
Jun 10, 2008·Journal of Neuroimmunology·Francesca AloisiBarbara Serafini
Jun 19, 2008·Annual Review of Neuroscience·Bruce D Trapp, Klaus-Armin Nave
Jun 24, 2008·Annals of Neurology·Leonora K FisnikuDavid H Miller
Oct 31, 2008·Lancet·Alastair Compston, Alasdair Coles
Feb 18, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M KhademiT Olsson
Apr 3, 2009·Brain : a Journal of Neurology·Josa M FrischerHans Lassmann
Sep 5, 2009·European Neurology·Trygve Holmøy
Oct 7, 2009·Multiple Sclerosis : Clinical and Laboratory Research·Eugene D FestaDiego Cadavid

❮ Previous
Next ❯

Citations

Jul 15, 2016·Expert Opinion on Biological Therapy·Sirin GandhiRobert Zivadinov
Feb 9, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Afsaneh Shirani, Olaf Stüve
May 14, 2019·Expert Review of Neurotherapeutics·Brandon WilbanksMoses Rodriguez
Mar 1, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·Paolo PreziosaMassimo Filippi
Apr 11, 2017·Neurologia i neurochirurgia polska·Vitalie VăcăraşAnca Dana Buzoianu
Jun 18, 2020·International Journal of Molecular Sciences·Kim M A De Kleijn, Gerard J M Martens
Aug 14, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Leoni RolfesSven G Meuth
Dec 29, 2020·Experimental Neurology·Yuxuan ZhangYong Jiang
Jan 24, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Paolo PreziosaMaria A Rocca
May 14, 2021·Multiple Sclerosis and Related Disorders·Alexander Cuculiza HenriksenJeppe Romme Christensen
Nov 14, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Paolo PreziosaMaria A Rocca
Jun 11, 2019·Seminars in Cancer Biology·Masahiro Yasunaga

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT01416181

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier & Cytokines

Some cytokines are able to cross the blood brain barrier through transport systems and enter the cerebrospinal fluid and interstitial fluid spaces. Here is the latest research on cytokines crossing the blood brain barrier and how this can affect tissues within the CNS.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

CNS & Neurological Disorders Drug Targets
Omer Anlar
World Journal of Clinical Cases
Alberto Gajofatto, Maria Donata Benedetti
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Per S Sørensen
© 2022 Meta ULC. All rights reserved